GCL
DMIIR

Glazer Capital LLC’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Glazer Capital LLC’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$152K Hold
1,899,899
– – ﹤0.01% 320
2025
Q4 		$266K Buy
+1,899,899
New +$271K 0.01% 257

Other funds holding DMIIR

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return

Glazer Capital LLC's DMIIR Position: Q1 2026 in Review

Glazer Capital LLC held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q1 2026 at 1,899,899 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #320.

Glazer Capital LLC first reported a position in DMIIR in Q4 2025 and has held it in 2 quarters since. The position peaked at $266K in Q4 2025. 57 funds tracked by Wall St. Rank hold DMIIR as of Q1 2026.

  • Glazer Capital LLC held 1,899,899 shares of Drugs Made In America Acquisition II Corp Right worth $152K as of Q1 2026.
  • Glazer Capital LLC left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Glazer Capital LLC's portfolio in Q1 2026, its #320 holding.
  • Glazer Capital LLC first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 2 quarters since.
  • Glazer Capital LLC's Drugs Made In America Acquisition II Corp Right position peaked at $266K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q1 2026.

Based on Glazer Capital LLC's 13F filing for Q1 2026, filed 14 May 2026.